

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the understanding and management... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2887/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2887" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention.">
            <meta name="og:description" content="Read the latest article version by Farhan Shahid, Eduard Shantsila, Gregory Y. H. Lip, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10962">
            <meta name="article-id" content="10176">
            <meta name="dc.title" content="Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention">
            <meta name="dc.description" content="Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. It is anticipated that by 2030 an estimated 14&ndash;17 million patients will be diagnosed with this most prevalent arrhythmia within the European Union. AF-related stroke confers a higher mortality and morbidity risk, and thus early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation (OAC) is crucial. Recent guidelines point to the use of non-vitamin K antagonist OACs (NOACs) where appropriate in stroke prevention of patients with non-valvular AF. At present, there are four NOACS available, with no direct head-to-head comparisons to suggest the superiority of one drug over another. 
Simple and practical risk assessment tools have evolved over the years to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision-making. At present, the CHA 2 DS 2 VASc (congestive heart failure, hypertension, age 65&ndash;74/&amp;gt;75, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex) score is recommended by many international guidelines as a simple and practical method of assessing stroke risk in such patients. Alongside this, use of the HAS BLED (hypertension systolic blood pressure &amp;gt;160 mmHg, abnormal liver/renal function [with creatinine &ge;200 &mu;mol/L], stroke, bleeding history or predisposition, labile international normalized ratio [range &amp;lt;60% of the time], elderly [&amp;gt;65], concomitant drugs/alcohol) score aims to identify patients at high risk of bleeding for more regular review and follow-up and draws attention to potentially reversible bleeding risk factors. 
The aim of this review article is to provide an overview of recent advances in the understanding and management of AF with a focus on stroke prevention.">
            <meta name="dc.subject" content="Atrial Fibrillation, screening, stroke, CHA2DS2VASc, HAS BLED, anti-coagulation, warfarin, non-vitamin k anti coagulants">
            <meta name="dc.creator" content="Shahid, Farhan">
            <meta name="dc.creator" content="Shantsila, Eduard">
            <meta name="dc.creator" content="Lip, Gregory Y. H.">
            <meta name="dc.date" content="2016/12/20">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.10176.1">
            <meta name="dc.source" content="F1000Research 2016 5:2887">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Atrial Fibrillation">
            <meta name="prism.keyword" content="screening">
            <meta name="prism.keyword" content="stroke">
            <meta name="prism.keyword" content="CHA2DS2VASc">
            <meta name="prism.keyword" content="HAS BLED">
            <meta name="prism.keyword" content="anti-coagulation">
            <meta name="prism.keyword" content="warfarin">
            <meta name="prism.keyword" content="non-vitamin k anti coagulants">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/12/20">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2887">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.10176.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2887">
            <meta name="citation_title" content="Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention">
            <meta name="citation_abstract" content="Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. It is anticipated that by 2030 an estimated 14&ndash;17 million patients will be diagnosed with this most prevalent arrhythmia within the European Union. AF-related stroke confers a higher mortality and morbidity risk, and thus early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation (OAC) is crucial. Recent guidelines point to the use of non-vitamin K antagonist OACs (NOACs) where appropriate in stroke prevention of patients with non-valvular AF. At present, there are four NOACS available, with no direct head-to-head comparisons to suggest the superiority of one drug over another. 
Simple and practical risk assessment tools have evolved over the years to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision-making. At present, the CHA 2 DS 2 VASc (congestive heart failure, hypertension, age 65&ndash;74/&amp;gt;75, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex) score is recommended by many international guidelines as a simple and practical method of assessing stroke risk in such patients. Alongside this, use of the HAS BLED (hypertension systolic blood pressure &amp;gt;160 mmHg, abnormal liver/renal function [with creatinine &ge;200 &mu;mol/L], stroke, bleeding history or predisposition, labile international normalized ratio [range &amp;lt;60% of the time], elderly [&amp;gt;65], concomitant drugs/alcohol) score aims to identify patients at high risk of bleeding for more regular review and follow-up and draws attention to potentially reversible bleeding risk factors. 
The aim of this review article is to provide an overview of recent advances in the understanding and management of AF with a focus on stroke prevention.">
            <meta name="citation_description" content="Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. It is anticipated that by 2030 an estimated 14&ndash;17 million patients will be diagnosed with this most prevalent arrhythmia within the European Union. AF-related stroke confers a higher mortality and morbidity risk, and thus early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation (OAC) is crucial. Recent guidelines point to the use of non-vitamin K antagonist OACs (NOACs) where appropriate in stroke prevention of patients with non-valvular AF. At present, there are four NOACS available, with no direct head-to-head comparisons to suggest the superiority of one drug over another. 
Simple and practical risk assessment tools have evolved over the years to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision-making. At present, the CHA 2 DS 2 VASc (congestive heart failure, hypertension, age 65&ndash;74/&amp;gt;75, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex) score is recommended by many international guidelines as a simple and practical method of assessing stroke risk in such patients. Alongside this, use of the HAS BLED (hypertension systolic blood pressure &amp;gt;160 mmHg, abnormal liver/renal function [with creatinine &ge;200 &mu;mol/L], stroke, bleeding history or predisposition, labile international normalized ratio [range &amp;lt;60% of the time], elderly [&amp;gt;65], concomitant drugs/alcohol) score aims to identify patients at high risk of bleeding for more regular review and follow-up and draws attention to potentially reversible bleeding risk factors. 
The aim of this review article is to provide an overview of recent advances in the understanding and management of AF with a focus on stroke prevention.">
            <meta name="citation_keywords" content="Atrial Fibrillation, screening, stroke, CHA2DS2VASc, HAS BLED, anti-coagulation, warfarin, non-vitamin k anti coagulants">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Farhan Shahid">
            <meta name="citation_author_institution" content="University of Birmingham Institute of Cardiovascular Sciences, Birmingham, UK">
            <meta name="citation_author" content="Eduard Shantsila">
            <meta name="citation_author_institution" content="University of Birmingham Institute of Cardiovascular Sciences, Birmingham, UK">
            <meta name="citation_author" content="Gregory Y. H. Lip">
            <meta name="citation_author_institution" content="University of Birmingham Institute of Cardiovascular Sciences, Birmingham, UK">
            <meta name="citation_author_institution" content="Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark">
            <meta name="citation_publication_date" content="2016/12/20">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2887">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.10176.1">
            <meta name="citation_firstpage" content="2887">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2887/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2887.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10962 /> <input type=hidden id=articleId name=articleId value=10176 /> <input type=hidden id=xmlUrl value="/articles/5-2887/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2887-v1.xml"> <input type=hidden id=article_uuid value=cc03691d-d215-4bfa-9ca3-ed03eb5c7920 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.10176.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.10176.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2887"
  },
  "headline": "Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention",
  "datePublished": "2016-12-20T16:34:19",
  "dateModified": "2016-12-20T16:34:19",
  "author": [
    {
      "@type": "Person",
      "name": "Farhan Shahid"
    },    {
      "@type": "Person",
      "name": "Eduard Shantsila"
    },    {
      "@type": "Person",
      "name": "Gregory Y. H. Lip"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. It is anticipated that by 2030 an estimated 14&ndash;17 million patients will be diagnosed with this most prevalent arrhythmia within the European Union. AF-related stroke confers a higher mortality and morbidity risk, and thus early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation (OAC) is crucial. Recent guidelines point to the use of non-vitamin K antagonist OACs (NOACs) where appropriate in stroke prevention of patients with non-valvular AF. At present, there are four NOACS available, with no direct head-to-head comparisons to suggest the superiority of one drug over another.
Simple and practical risk assessment tools have evolved over the years to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision-making. At present, the CHA2DS2VASc (congestive heart failure, hypertension, age 65&ndash;74/&amp;gt;75, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex) score is recommended by many international guidelines as a simple and practical method of assessing stroke risk in such patients. Alongside this, use of the HAS BLED (hypertension systolic blood pressure &amp;gt;160 mmHg, abnormal liver/renal function [with creatinine &ge;200 &mu;mol/L], stroke, bleeding history or predisposition, labile international normalized ratio [range &amp;lt;60% of the time], elderly [&amp;gt;65], concomitant drugs/alcohol) score aims to identify patients at high risk of bleeding for more regular review and follow-up and draws attention to potentially reversible bleeding risk factors.
The aim of this review article is to provide an overview of recent advances in the understanding and management of AF with a focus on stroke prevention."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2887.html",
            "name": "Recent advances in the understanding and management of atrial fibrillation:..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the understanding and management of atrial fibrillation:... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10962 data-id=10176 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10176.1" data-recommended="" data-doi="10.12688/f1000research.10176.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2887/v1/pdf?article_uuid=cc03691d-d215-4bfa-9ca3-ed03eb5c7920" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-10176-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-10176-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-10176-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Shahid F, Shantsila E and Lip GYH. Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2887 (<a class=new-orange href="https://doi.org/10.12688/f1000research.10176.1" target=_blank>https://doi.org/10.12688/f1000research.10176.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-10176-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=10176 id=track-article-signin-10176 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10176?target=/articles/5-2887.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10962 /> <input name=articleId type=hidden value=10176 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Farhan Shahid<a href="https://orcid.org/0000-0001-7635-5703" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7635-5703</div><sup>1</sup>,&nbsp;</span><span class="">Eduard Shantsila<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:g.y.h.lip@bham.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Gregory Y. H. Lip</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Farhan Shahid<a href="http://orcid.org/0000-0001-7635-5703" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7635-5703</div><sup>1</sup>,&nbsp;</span><span class="">Eduard Shantsila<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:g.y.h.lip@bham.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Gregory Y. H. Lip</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 20 Dec 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.10176.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> University of Birmingham Institute of Cardiovascular Sciences, Birmingham, UK<br/> <sup>2</sup> Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19064-18640></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19065-18632></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19063-18637></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. It is anticipated that by 2030 an estimated 14–17 million patients will be diagnosed with this most prevalent arrhythmia within the European Union. AF-related stroke confers a higher mortality and morbidity risk, and thus early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation (OAC) is crucial. Recent guidelines point to the use of non-vitamin K antagonist OACs (NOACs) where appropriate in stroke prevention of patients with non-valvular AF. At present, there are four NOACS available, with no direct head-to-head comparisons to suggest the superiority of one drug over another.<br/> Simple and practical risk assessment tools have evolved over the years to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision-making. At present, the CHA<sub>2</sub>DS<sub>2</sub>VASc (congestive heart failure, hypertension, age 65–74/&gt;75, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex) score is recommended by many international guidelines as a simple and practical method of assessing stroke risk in such patients. Alongside this, use of the HAS BLED (hypertension systolic blood pressure &gt;160 mmHg, abnormal liver/renal function [with creatinine ≥200 μmol/L], stroke, bleeding history or predisposition, labile international normalized ratio [range &lt;60% of the time], elderly [&gt;65], concomitant drugs/alcohol) score aims to identify patients at high risk of bleeding for more regular review and follow-up and draws attention to potentially reversible bleeding risk factors.<br/> The aim of this review article is to provide an overview of recent advances in the understanding and management of AF with a focus on stroke prevention. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Atrial Fibrillation, screening, stroke, CHA2DS2VASc, HAS BLED, anti-coagulation, warfarin, non-vitamin k anti coagulants </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Gregory Y. H. Lip (<a href="mailto:g.y.h.lip@bham.ac.uk">g.y.h.lip@bham.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Gregory Y. H. Lip </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Farhan Shahid and Eduard Shantsila declare that they have no competing interests. Gregory Y. H. Lip has served as a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Shahid F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Shahid F, Shantsila E and Lip GYH. Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2887 (<a href="https://doi.org/10.12688/f1000research.10176.1" target=_blank>https://doi.org/10.12688/f1000research.10176.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 20 Dec 2016, <b>5</b>(F1000 Faculty Rev):2887 (<a href="https://doi.org/10.12688/f1000research.10176.1" target=_blank>https://doi.org/10.12688/f1000research.10176.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 20 Dec 2016, <b>5</b>(F1000 Faculty Rev):2887 (<a href="https://doi.org/10.12688/f1000research.10176.1" target=_blank>https://doi.org/10.12688/f1000research.10176.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e191>Introduction</h2><p class="" id=d6966e194>Atrial fibrillation (AF) is associated with a five-fold increase in the risk of stroke, and AF-related stroke patients have a higher mortality and greater morbidity than patients with non-AF-related stroke<sup><a href="#ref-1">1</a></sup>. It is anticipated that by 2030 an estimated 14–17 million patients will be diagnosed with this most prevalent arrhythmia within the European Union.</p><p class="" id=d6966e201>Over recent years, the need for early detection and use of appropriate thromboprophylaxis have proved to be central in the prevention of AF-related stroke, which in itself carries a higher morbidity and mortality than non-AF-related stroke<sup><a href="#ref-2">2</a></sup>. The use of oral anticoagulation (OAC), whether with the vitamin K antagonists (VKAs, e.g. warfarin) or, more recently, the non-VKA OACs (NOACs), results in a marked reduction in stroke and all-cause mortality<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. Many guidelines now emphasize that the default should be to offer thromboprophylaxis to all patients with AF, unless “truly low risk” is evident such that OAC confers no advantage<sup><a href="#ref-5">5</a></sup>. Aspirin has been proven to offer little net clinical benefit and is not recommended for stroke prevention in AF<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d6966e223>Various systemic reviews have highlighted the common risk factors associated with AF-related stroke<sup><a href="#ref-1">1</a>,<a href="#ref-7">7</a></sup>. There are a number of independent “stroke risk factors”, but each may not necessarily contribute equally to stroke risk in AF. To aid in the practical evaluation of stroke risk in AF, various risk stratification schemes have been proposed to aid decision-making regarding thromboprophylaxis<sup><a href="#ref-8">8</a></sup>. Such schemes are based on risk factors derived from the non-VKA arms of the historical clinical trial cohorts, large observational studies, and consensus opinion, and the resulting schemas vary greatly in their complexity and number of risk factors<sup><a href="#ref-9">9</a></sup>. Even one stroke risk factor confers excess risk of stroke and mortality. In essence, patients with risk factors should be offered OAC unless contraindicated, given the positive net clinical benefit for treating such patients<sup><a href="#ref-6">6</a>,<a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>.</p><p class="" id=d6966e251>The aim of this review article is to provide an overview of the recent advances in the diagnosis and management of patients with AF with a focus on stroke prevention.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e257>Pathophysiology of atrial fibrillation and its complications: a brief overview</h2><p class="" id=d6966e260>External stressors such as hypertension, diabetes mellitus, and AF itself can stimulate a process of atrial remodeling and subsequent fibrosis, which acts as a substrate for AF (along with other cardiac arrhythmias)<sup><a href="#ref-12">12</a></sup>. The structural remodeling that takes place leads to an alteration in the electrical conduction pathway in the atrium, leading to a low threshold re-entry circuit and propagation of arrhythmias<sup><a href="#ref-13">13</a></sup>. AF itself takes place after the process of cardiac remodeling and fibrosis. Thus, treatment aimed at minimizing this adverse remodeling pathway should be initiated at the earliest opportunity<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d6966e275>The rhythm of AF itself along with the structural remodeling that takes place predisposes the atrial myocardium to a prothrombotic state (especially within the left atrial appendage)<sup><a href="#ref-15">15</a></sup>. Furthermore, short episodes of AF can cause myocardial damage within the atrium, which in turn stimulates the release of prothrombotic factors onto the endothelial surface, leading to the aggregation of platelets. This, in part, explains why even short episodes of AF can confer long-term stroke risk<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>.</p><p class="" id=d6966e289>The mechanisms that cause AF are heterogeneous. For example, in patients with structural heart disease, there is a prolonged atrial refractory period that acts as the substrate to AF, whereas patients who develop AF in the absence of ischemic heart disease often have a shortening of the atrial refractory period due to the downregulation of inward calcium channels and the upregulation of potassium inward currents<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. This alteration in calcium handling by the atrial myocardium in line with atrial remodeling appears to be the most plausible explanation of how changes in autonomic tone can initiate AF<sup><a href="#ref-20">20</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e306>Screening for atrial fibrillation</h2><p class="" id=d6966e309>The adverse outcomes associated with AF are preventable by the appropriate and timely introduction of medical therapy. Given the fact that AF-related stroke carries with it a poorer outcome than does non-AF-related stroke, the appropriate use of OACs provides a means by which the detrimental thromboembolic effects of AF can be avoided.</p><p class="" id=d6966e312>In an ideal setting, AF would be negated by the introduction of effective primary preventative therapies, with the next best option being the early initiation of treatment if and when AF is detected. However, with 30% of AF being found in asymptomatic patients, how best to detect this arrhythmia is of some growing concern<sup><a href="#ref-21">21</a></sup>. A proportion of patients are fortunate enough to have AF detected by chance, often because of routine medical examinations for other reasons.</p><p class="" id=d6966e319>The absence of symptoms does not remove or reduce the risk of associated stroke, with this cohort of patients often found to have a higher CHA<sub>2</sub>DS<sub>2</sub>VASc (congestive heart failure, hypertension, age 65–74/&gt;75, diabetes mellitus, stroke/transient ischemic attack [TIA]/thromboembolism, vascular disease, female sex) score than symptomatic patients<sup><a href="#ref-22">22</a></sup>. Unfortunately, for the vast majority of patients with asymptomatic AF, the first opportunity to detect this arrhythmia is in the context of an acute stroke<sup><a href="#ref-2">2</a></sup>. One in five ischemic strokes are attributable to AF, of which greater than 20% represent AF diagnosed after the stroke event<sup><a href="#ref-23">23</a></sup>. Without question, such events could have been avoided with earlier detection and initiation of OAC.</p><p class="" id=d6966e340>The suggestion of widespread screening for AF is not new, with previous studies within community healthcare practices and meta-analyses showing a clear benefit<sup><a href="#ref-24">24</a></sup>. However, the optimal method by which to go about detecting asymptomatic AF is unclear.</p><p class="" id=d6966e348>The cryptogenic stroke and underlying AF (CRYSTAL AF) study was designed to evaluate whether continuous cardiac monitoring in the way of an implantable cardiac monitor was superior to detecting AF versus “conventional follow-up” in patients with a cryptogenic stroke or TIA<sup><a href="#ref-25">25</a></sup>. During the 3-year study period, 447 patients were enrolled into this study. Of the 221 patients receiving an implantable cardiac monitor, 8.9% had AF detected at 6 months versus only 1.4% in the control group. Importantly, the benefit of prolonged monitoring was maintained at 12-month follow-up, with a 12.4% AF detection rate in the implantable cardiac monitoring group. Most poignantly, ischemic stroke or TIA occurred in 11 patients with the intracardiac monitor versus 18 patients in the control group. This favorable outlook in the intracardiac monitor group corresponded to a higher use of OACs at the 6-month interval (10.1% versus only 4.6% in the control group).</p><p class="" id=d6966e355>The EMBRACE trial was another randomized controlled trial aimed at quantifying the benefit of longer monitoring periods for patients with potential AF in the context of secondary prevention of stroke<sup><a href="#ref-26">26</a></sup>. Of the 572 patients enrolled, 16.2% of patients had at least 30 seconds of AF detected over 90 days of monitoring compared to only 3.2% in those who underwent 24-hour monitoring. This correlated with an absolute difference of OAC uptake of 7.5% in favor of prolonged monitoring.</p><p class="" id=d6966e362>Recently, the SEARCH AF study analyzed the feasibility and cost-effectiveness of opportunistic, community-based screening in Australia in patients aged over 65<sup><a href="#ref-22">22</a></sup>. A structured screening method including a brief history and pulse palpation, and a handheld phone-based ECG recording was taken. A total of 1000 pharmacy customers were screened with newly identified AF in 1.5% of the cohort. The sensitivity and specificity for this automated iECG algorithm was 98.5% and 91.4%, respectively. A cost-effective analysis showed that most benefit was observed in relation to quality-adjusted life years in those patients in whom anticoagulation adherence was optimal.</p><p class="" id=d6966e369>With the fruition of large randomized studies showing a clear benefit for prolonged monitoring in patients at risk of AF along with a cost benefit, guidelines will no doubt begin to incorporate a more structured approach for the detection of asymptomatic AF. At present, pulse palpation and ECG rhythm strip are recommended for primary prevention and short-term monitoring of at least 72 hours in those patients having suffered a TIA or ischemic stroke<sup><a href="#ref-5">5</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e379>How much atrial fibrillation is significant?</h2><p class="" id=d6966e382>For a long time, evidence-based guidelines have questioned whether “AF burden” is relevant to stroke risk. As such, current guidelines do not distinguish between types of AF with regard to thromboprophylaxis, as observational data suggest that stroke risk is similar regardless of AF subtype in the presence of stroke risk factors<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. The European Atrial Fibrillation Trial (EAFT) with a follow-up of 594 patient-years found AF duration &gt;1 year was an independent risk factor for secondary stroke<sup><a href="#ref-29">29</a></sup>.</p><p class="" id=d6966e396>One meta-analysis examined stroke rates in 134,847 patients with paroxysmal AF (PAF) versus permanent AF off anticoagulation and reported an odds ratio (OR) of 0.75 (95% confidence interval [CI] 0.61–0.93) in favor of less stroke risk in patients with PAF<sup><a href="#ref-30">30</a></sup>. In anticoagulated patients, the OR also favored patients with PAF (OR 0.77, 95% CI 0.68–0.88). This was confirmed in a further systematic review and meta-analysis<sup><a href="#ref-31">31</a></sup>.</p><p class="" id=d6966e407>Furthermore, analysis of data from “The AF Clopidogrel Trial with Irbesartan for prevention of vascular events” (ACTIVE-A) and “Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in AF Patients Who Have Failed or Are Unsuitable for VKA Treatment” (AVERROES) trials also pointed to the idea that a pattern of AF was a strong independent predictor of stroke risk, second only to previous TIA or stroke<sup><a href="#ref-32">32</a></sup>. In the 6,563 patients included in this analysis, permanent AF had an annual stroke risk of 4.2% compared to 2.1% with PAF and 3.0% with persistent AF. Hazard ratios of 1.83 for permanent AF versus PAF and 1.44 for persistent AF versus PAF were found, respectively. A subanalysis of the “Rivaroxaban Once daily oral direct factor Xa inhibition compared with VKA for prevention of stroke and Embolism Trial in AF” (ROCKET AF) also found that anticoagulated patients with persistent AF (11,548 patients) were at higher risk of stroke versus those with PAF (2,514 patients)<sup><a href="#ref-33">33</a></sup>. Patients with persistent AF had higher rates of stroke and all-cause mortality (adjusted rates for stroke 2.18 versus 1.73 events/100 patient-years, p=0.048).</p><p class="" id=d6966e418>Despite trials showing that the pattern of AF has an impact on stroke risk, there appears to be marked heterogeneity amongst the respective trials, making comparisons difficult. Furthermore, the fluctuations in OAC use between trials makes conclusive links between patterns of AF and stroke risk difficult to extrapolate. Within types of AF, there can be marked heterogeneity. In PAF, for example, those with one paroxysm once a year are labeled as PAF, as would a patient with paroxysms of AF 364 days per year.</p><p class="" id=d6966e422>Therefore, at present, patients diagnosed with AF, regardless of type or duration, require assessment for stroke and bleeding risk using guideline recommendations<sup><a href="#ref-5">5</a>,<a href="#ref-34">34</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e435>Anticoagulation in patients with atrial fibrillation</h2><p class="" id=d6966e438>Stroke prevention in patients with non-valvular AF requires careful consideration of the risk versus benefit of starting OAC therapy. Stroke and bleeding risk factors in patients with AF are not homogeneous, and risk stratification schemes such as the CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS BLED (hypertension systolic blood pressure &gt;160 mmHg, abnormal liver/renal function [with creatinine ≥200 μmol/L], stroke, bleeding history or predisposition, labile international normalized ratio [INR] [eg. Time in Therapeutic Range &lt;60%], elderly<sup><a href="#ref-65">&gt;65</a></sup>, concomitant drugs/alcohol) scores are well validated and provide a simple and quick yet concise method of assessing a patient’s suitability for anticoagulation without the necessity of complex composite scores or multiple biomarkers<sup><a href="#ref-8">8</a>,<a href="#ref-35">35</a></sup>.</p><p class="" id=d6966e458>For more than 50 years, the VKAs, e.g. warfarin, have been the mainstay of anticoagulation in patients with non-valvular AF, significantly reducing stroke and mortality<sup><a href="#ref-36">36</a></sup>. Aspirin monotherapy, on the other hand, is ineffective for stroke prevention and indeed unsafe<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d6966e469>In 2009 came the introduction of the NOACs, which revolutionized the management of stroke prevention in non-valvular AF. Initially referred to as new or novel OACs, or sometimes direct OACs (DOACs), the NOAC acronym has been retained to refer to non-VKA OACs<sup><a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup>. The four major drugs (dabigatran, apixaban, rivaroxaban, and edoxaban) compare favorably with warfarin, showing at least non-inferiority in regards to stroke prevention, with a superior safety profile with regard to major bleeding<sup><a href="#ref-39">39</a>–<a href="#ref-42">42</a></sup>. Recent data from ancillary analyses of the major trials show that patients taking NOACs are at 30–50% lower risk of major bleeding than with warfarin<sup><a href="#ref-43">43</a>–<a href="#ref-45">45</a></sup>. As yet, no head-to-head trials amongst the NOACs have been undertaken.</p><div class=section><a name=d6966e493 class=n-a></a><h3 class=section-title>Dabigatran</h3><p class="" id=d6966e498>Dabigatran is an oral direct thrombin inhibitor, binding to the active catalytic site of thrombin in a reversible manner. This action blocks the conversion of fibrinogen to fibrin. Dabigatran is available as a non-active pro-drug that is converted to its active form <i>in vivo</i> (gut mucosa, liver, and plasma). Renal elimination is the dominant pathway of excretion for this anticoagulant (up to 80%).</p><p class="" id=d6966e504>The efficacy and safety of dabigatran was first evaluated in a large randomized controlled study in 2009. The RE-LY study compared dabigatran (150 and 110 mg bis die [b.d.]) to dose-adjusted warfarin. Efficacy analysis showed non-inferiority of the 110 mg b.d. dose (1.54%/year) and superiority of the 150 mg b.d. dose (1.11%/year) compared to warfarin (1.71%/year) for the prevention of stroke and systemic embolism<sup><a href="#ref-39">39</a>,<a href="#ref-46">46</a></sup>. Both dosing regimens were associated with lower risk of intracranial hemorrhage (ICH) compared to warfarin<sup><a href="#ref-39">39</a>,<a href="#ref-46">46</a></sup>. This was consistent across a range of stroke risk strata<sup><a href="#ref-47">47</a></sup>. Of note, however, was the higher gastrointestinal bleeding risk with dabigatran 150 mg b.d. (1.51% versus 1.02%/year for warfarin)<sup><a href="#ref-39">39</a></sup>. Dabigatran 150 mg b.d. was associated with a lower cardiovascular mortality<sup><a href="#ref-39">39</a>,<a href="#ref-46">46</a></sup>, which has been confirmed in a recent meta-analysis of observational data<sup><a href="#ref-48">48</a></sup>. Since the RE-LY trial, subsequent “real world” evidence has provided further supportive evidence for the superiority of dabigatran over warfarin<sup><a href="#ref-49">49</a>–<a href="#ref-51">51</a></sup>.</p></div><div class=section><a name=d6966e550 class=n-a></a><h3 class=section-title>Apixaban</h3><p class="" id=d6966e555>Apixaban is a factor Xa inhibitor that is approved for patients with non-valvular AF in need of stroke prevention. Major trials excluded patients with a creatinine level of 2.5 mm/dL or a creatinine clearance of &lt;25 mL/min/1.73 m<sup>2</sup>. A dose reduction is available from 5 mg b.d. to 2.5 mg b.d. for patients who have two of the following factors: age ≥80 years, weight &lt;60 kg, or serum creatinine &gt;1.5 mg/dL<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>.</p><p class="" id=d6966e568>In 2011, the AVERROES trial showed a clear benefit of apixaban over aspirin<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. There were no significant differences in the risk of major bleeding or ICH between apixaban and aspirin. In 2012, the ARISTOTLE (apixaban for the reduction in stroke and other thrombotic events in atrial fibrillation) trial compared apixaban to warfarin in 18,201 patients<sup><a href="#ref-41">41</a></sup> and found apixaban to be superior to warfarin for the primary outcome of stroke and systemic embolism (1.27% versus 1.6%, respectively). Apixaban was also associated with a significantly lower incidence of major bleeding, ICH, and mortality<sup><a href="#ref-56">56</a></sup>. In recent observational data, apixaban has been shown to provide greater treatment persistence versus warfarin in AF patients, which in itself could lead to fewer cardioembolic events and stroke burden<sup><a href="#ref-57">57</a></sup>.</p></div><div class=section><a name=d6966e591 class=n-a></a><h3 class=section-title>Rivaroxaban</h3><p class="" id=d6966e596>The ROCKET AF trial enrolled 14,262 patients at moderate to high risk of stroke to either warfarin (target INR 2–3 or rivaroxaban 20 mg, with a dose reduction to 15 mg in those with creatinine clearance of 30–49 mL/min)<sup><a href="#ref-40">40</a></sup>. Rivaroxaban was non-inferior to warfarin for the composite end point of stroke and systemic embolism, with similar rates of major bleeding and ICH, but rivaroxaban had a higher incidence of gastrointestinal bleeding compared to warfarin. Prospective, non-interventional registries have provided reassuring data for rivaroxaban compared to VKAs, along with better treatment compliance<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>.</p></div><div class=section><a name=d6966e611 class=n-a></a><h3 class=section-title>Edoxaban</h3><p class="" id=d6966e616>Like apixaban and rivaroxaban, edoxaban is a selective factor Xa inhibitor and was tested in the phase III ENGAGE AF TIMI-48 trial, which enrolled 21,105 patients to the high-dose edoxaban strategy arm, the low-dose strategy arm, or warfarin<sup><a href="#ref-42">42</a></sup>. The high-dose edoxaban arm was not inferior to warfarin for the primary endpoint of stroke and systemic embolism, with a significant reduction in major bleeding and ICH, although there were more gastrointestinal bleeds with edoxaban 60 mg versus warfarin. Efficacy appeared to diminish in patients with a high creatinine clearance, with edoxaban 60 mg once daily having a trend towards higher strokes with creatinine clearance of ≥95 mL/min, leading to a US Food and Drug Administration (FDA) black box for use in such patients. “Real world data” for edoxaban are limited, although indirect comparisons of edoxaban to anti-platelet therapies or placebo have been published<sup><a href="#ref-60">60</a></sup>.</p></div><div class=section><a name=d6966e628 class=n-a></a><h3 class=section-title>Reversal agents</h3><p class="" id=d6966e633>There remain concerns regarding the bleeding risk with the NOACs and – until recently – the lack of a specific antidote<sup><a href="#ref-61">61</a></sup>. With the introduction of idarucizumab (a fully humanized antibody fragment) recently licensed for use in patients taking dabigatran, such concerns may be unwarranted<sup><a href="#ref-62">62</a>–<a href="#ref-64">64</a></sup>. In addition, andexanet alfa (a truncated form of enzymatically inactive factor Xa which binds factor Xa inhibitors and reverses their anticoagulant effects) was investigated for the reversal of oral factor Xa inhibitors<sup><a href="#ref-65">65</a></sup>. Also under development is ciraparantag<sup><a href="#ref-66">66</a></sup>, which is at an earlier stage of development as a universal reversal agent for all NOACs.</p></div><div class=section><a name=d6966e656 class=n-a></a><h3 class=section-title>Practical issues</h3><p class="" id=d6966e661>As part of the initiation of NOAC therapy, the involvement of patient education is of central importance<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup>. The patient must be made aware that missing a dose of NOAC potentially removes the stroke protection due to their relatively short half-life versus that of VKAs. Guidelines also emphasize the need for patient education and involvement in decision-making when deciding on the most appropriate anticoagulation<sup><a href="#ref-5">5</a></sup>. Thus, NOACs provide a better, safer, and more convenient anticoagulation option with a greater net clinical benefit<sup><a href="#ref-69">69</a></sup>. Accordingly, NOACs are now a well-established option (in addition to warfarin) for the prevention of thromboembolic events in non-valvular AF and venous thromboembolism and are given preference over warfarin in many updated clinical guidelines on the management of AF<sup><a href="#ref-5">5</a>,<a href="#ref-34">34</a>,<a href="#ref-70">70</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e694>How do clinical trial results compare with “real world data”?</h2><p class="" id=d6966e697>Clinical trial data are not always reproducible in everyday clinical practice. Reassuringly, NOACs have continued to show a net clinical benefit when introduced in “real world” clinical settings, with the real world observational evidence being complementary and supportive of the trial results.</p><p class="" id=d6966e700>Dabigatran has been licensed and available the longest, hence many comparisons to warfarin in real world studies are with this direct thrombin inhibitor<sup><a href="#ref-71">71</a></sup>. The real world results for dabigatran have largely echoed the clinical trial findings<sup><a href="#ref-72">72</a></sup>. In a large US database compromising 12,793 patients with a mean age of 74 years, dabigatran was superior to warfarin with regard to stroke prevention (adjusted hazard ratio 0.73, 95% CI 0.55–0.97) with a lower incidence of major bleeding (adjusted hazard ratio for intracranial bleeding 0.49 [0.3–0.79])<sup><a href="#ref-73">73</a></sup>. Other registry data have shown similar findings<sup><a href="#ref-49">49</a>,<a href="#ref-74">74</a></sup>. A recent meta-analysis of these observational data (with over 20 studies, totaling 711,298 patients) found a lower risk of ischemic stroke compared to warfarin (hazard ratio 0.86, CI 0.74–0.99) with a lower incidence of intracranial bleeding (0.45, CI 0.38–0.52) but higher risk of gastrointestinal bleeding (1.13, CI 1.00–1.28)<sup><a href="#ref-51">51</a></sup>.</p><p class="" id=d6966e726>Real world data regarding rivaroxaban and apixaban have recently also gathered pace. The XANTUS observational study was a prospective, observational study of patients treated with rivaroxaban for stroke prevention in AF. A total of 6,784 patients were initiated on rivaroxaban across 311 centers in Europe, Israel, and Canada. Rates of stroke were found to be low in this cohort of patients, with 43 patients suffering a stroke and 43 a major bleed (0.7 events per 100 patient-years and 2.1 events per 100 patient-years, respectively)<sup><a href="#ref-75">75</a></sup>. More recently, Coleman <i>et al</i>. compared data for AF patients newly started on rivaroxaban, apixaban, or warfarin<sup><a href="#ref-76">76</a></sup>. When compared to warfarin, rivaroxaban was associated with a reduction in ICH (0.49% versus 0.96% per year, hazard ratio 0.53, CI 0.35–0.79), with a non-significant reduction in ischemic stroke (0.54% versus 0.83% per year, hazard ratio 0.71, CI 0.47–1.07).</p><p class="" id=d6966e740>The current industry-funded GARFIELD AF registry aims to recruit between 55,000 and 60,000 patients with AF, analyzing trends of anticoagulant use in patients with AF. In the fourth cohort of GARFIELD AF, more than 70% of AF patients are anticoagulated, with a growing proportion being initiated on NOAC therapy over warfarin (37%), and OAC use was associated with a 35% lower risk of death<sup><a href="#ref-77">77</a></sup>. Other registry data have since been published for comparative effectiveness and safety data for dabigatran, rivaroxaban, apixaban, and warfarin<sup><a href="#ref-50">50</a>,<a href="#ref-78">78</a>,<a href="#ref-79">79</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e760>What does the future hold for non-vitamin K antagonist oral anticoagulation and stroke prevention?</h2><p class="" id=d6966e763>With the superior net clinical benefit of NOACs over VKAs, the opportunity to offer anticoagulation to a wider spectrum of AF patients is clearly evident. Previously, with the use of warfarin, the inconvenience of multiple blood tests for INR monitoring and food/drug interactions meant not all eligible patients would accept or be offered OAC for stroke prophylaxis. With the need for minimal monitoring in regards to blood tests and a reduction in major bleeding risk, older and arguably frailer populations who have AF will now have the benefit of stroke prophylaxis without increasing their major bleeding risk to unacceptable levels. At present, patients with mechanical prosthetic heart valves are not eligible for NOAC therapy.</p><div class=section><a name=d6966e766 class=n-a></a><h3 class=section-title>What do we do for patients not suitable for OAC?</h3><p class="" id=d6966e771>In a minority of cases, OAC may be absolutely contraindicated despite patients being at high risk of AF-related stroke. Aspirin is no longer recommended for stroke prophylaxis in patients with AF owing to its inferior efficacy in stroke prophylaxis along with an unacceptable heightened bleeding risk<sup><a href="#ref-6">6</a></sup>. After careful consideration by a multidisciplinary team and discussion with the patient, alternative interventions need to be sought.</p><p class="" id=d6966e778>Recent trial evidence has focused on the feasibility of left atrial appendage (LAA) closure devices. The PROTECT-AF trial compared the LAA device Watchman to warfarin in a randomized multi-center study of 707 patients, where patients were assigned in a 2:1 fashion to either LAA closure device with discontinuation of warfarin or warfarin with an INR target of 2–3<sup><a href="#ref-80">80</a></sup>. Primary end point data (stroke, cardiovascular death, and systemic embolization) showed non-inferiority of the Watchman device over warfarin (event rate 3 per 100 patient-years in the intervention group versus 4.9 per 100 patient-years in the warfarin-treated cohort). Primary safety events (major bleeding, pericardial effusion, and device embolization) were more frequent in the intervention group than in the control group (7.4% per 100 patient-years versus 4.4% per 100 patients-years). Of note, 15% of patients in this trial remained on warfarin despite being in the interventional arm. At 3.8-year follow-up, long-term data from the PROTECT-AF trial appear to be consistent with initial analysis showing non-inferiority of Watchman to warfarin. The PREVAIL trial compared Watchman to warfarin in 407 high-risk patients (CHA<sub>2</sub>DS<sub>2</sub>VASc = 3.8)<sup><a href="#ref-81">81</a></sup>. The primary efficacy end points of stroke (hemorrhagic and ischemic), systemic embolization, and cardiovascular/unexplained death were similar (6.4% versus 6.3%) but did not meet the criteria for non-inferiority, meaning there was a potential for the device to be inferior to standard care. A recent patient-level meta-analysis found lower rates of hemorrhagic stroke with the Watchman device and non-inferior differences in the composite end point of all-cause stroke or systemic embolization. Of note, ischemic stroke per se occurred nearly twice as often in the Watchman arm compared to the warfarin arm (hazard ratio 1.95, p = 0.05)<sup><a href="#ref-82">82</a></sup>.</p><p class="" id=d6966e799>However, evidence also exists for improvements in quality of life<sup><a href="#ref-83">83</a></sup>, reduction in late bleeding<sup><a href="#ref-84">84</a></sup>, and economic benefit<sup><a href="#ref-85">85</a></sup> with the use of LAA closure devices. More recently, other devices in addition to Watchman (although not yet FDA approved) have provided favorable outcomes<sup><a href="#ref-86">86</a>,<a href="#ref-87">87</a></sup>.</p><p class="" id=d6966e821>At present, we still do not know whether OAC-ineligible patients benefit from LAA closure, as the present trials were not inclusive of such patients, or how an LAA closure device would compare against the NOACs. Present treatment guidelines do state non-inferiority of LAA closure to standard-care warfarin, but this should be treated with caution as more data from long-term follow-up emerge.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6966e828>Conclusion</h2><p class="" id=d6966e831>The detection and management of AF is a core component of stroke prevention in the AF patient population. A proposed method of screening and managing AF is shown in <a href="#f1">Figure 1</a>. With an increasingly aging population with multiple comorbidities, the diagnosis of AF becomes more likely. Most guidelines advocate simple opportunistic pulse check in primary care practices, but more prolonged forms of monitoring increase the yield of AF detection. With the introduction of NOACs, there appears to be little reason not to offer anticoagulation to all AF patients with one or more stroke risk factors, apart from those truly deemed “low risk” using the CHA<sub>2</sub>DS<sub>2</sub>VASc score.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10962/9541916b-ebb8-412d-81eb-3c093cd6a021_figure1.gif"><img alt="9541916b-ebb8-412d-81eb-3c093cd6a021_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10962/9541916b-ebb8-412d-81eb-3c093cd6a021_figure1.gif"></a><div class=caption><h3>Figure 1. Proposed algorithm for the detection and management of atrial fibrillation (AF).</h3><p id=d6966e853>CHA<sub>2</sub>DS<sub>2</sub>VASc, congestive heart failure, hypertension, age 65–74/&gt;75, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex; ECG, electrocardiogram; HAS BLED, hypertension systolic blood pressure &gt;160 mmHg, abnormal liver/renal function [with creatinine ≥200 μmol/L], stroke, bleeding history or predisposition, labile international normalized ratio [range &lt;60% of the time], elderly [&gt;65], concomitant drugs/alcohol; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant.</p></div></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d6966e1 class=n-a></a><h2 class=main-title id=d7264>Competing interests</h2><p class=metadata-entry><a name=d6966e114 class=n-a></a><p id=d6966e116> Farhan Shahid and Eduard Shantsila declare that they have no competing interests. Gregory Y. H. Lip has served as a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo.</p></p></div><div class=back-section><a name=d6966e1 class=n-a></a><h2 class=main-title id=d7266>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d6966e870 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d7531>References</h2><div class="section ref-list"><a name=d6966e870 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d6966e877 class=n-a></a>Pisters R, Lane DA, Marin F, <i> et al.</i>: Stroke and thromboembolism in atrial fibrillation. <i>Circ J.</i> 2012; <b>76</b>(10): 2289–304. <a target=xrefwindow id=d6966e888 href="http://www.ncbi.nlm.nih.gov/pubmed/23001018">PubMed Abstract </a> | <a target=xrefwindow id=d6966e891 href="https://doi.org/10.1253/circj.CJ-12-1036">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718464063"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e900 class=n-a></a>Martinez C, Katholing A, Freedman SB: Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. <i>Thromb Haemost.</i> 2014; <b>112</b>(2): 276–86. <a target=xrefwindow id=d6966e908 href="http://www.ncbi.nlm.nih.gov/pubmed/24953051">PubMed Abstract </a> | <a target=xrefwindow id=d6966e911 href="https://doi.org/10.1160/TH4-04-0383">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718464063">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718304413"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e924 class=n-a></a>Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. <i>Ann Intern Med.</i> 2007; <b>146</b>(12): 857–67. <a target=xrefwindow id=d6966e932 href="http://www.ncbi.nlm.nih.gov/pubmed/17577005">PubMed Abstract </a> | <a target=xrefwindow id=d6966e935 href="https://doi.org/10.7326/0003-4819-146-12-200706190-00007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718304413">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d6966e948 class=n-a></a>Lip GY, Clemens A, Noack H, <i> et al.</i>: Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. <i>Thromb Haemost.</i> 2014; <b>111</b>(5): 933–42. <a target=xrefwindow id=d6966e959 href="http://www.ncbi.nlm.nih.gov/pubmed/24326736">PubMed Abstract </a> | <a target=xrefwindow id=d6966e962 href="https://doi.org/10.1160/TH13-09-0734">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d6966e971 class=n-a></a>Kirchhof P, Benussi S, Kotecha D, <i> et al.</i>: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Eur Heart J.</i> 2016; <b>37</b>(38): 2893–2962. <a target=xrefwindow id=d6966e982 href="http://www.ncbi.nlm.nih.gov/pubmed/27567408">PubMed Abstract </a> | <a target=xrefwindow id=d6966e985 href="https://doi.org/10.1093/eurheartj/ehw210">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d6966e995 class=n-a></a>Lip GY, Skjøth F, Nielsen PB, <i> et al.</i>: Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. <i>Thromb Haemost.</i> 2015; <b>114</b>(4): 826–34. <a target=xrefwindow id=d6966e1006 href="http://www.ncbi.nlm.nih.gov/pubmed/26223245">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1009 href="https://doi.org/10.1160/TH15-07-0565">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d6966e1018 class=n-a></a>Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: a systematic review. <i>Neurology.</i> 2007; <b>69</b>(6): 546–54. <a target=xrefwindow id=d6966e1026 href="http://www.ncbi.nlm.nih.gov/pubmed/17679673">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1029 href="https://doi.org/10.1212/01.wnl.0000267275.68538.8d">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d6966e1038 class=n-a></a>Lip GY: Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? <i>Eur Heart J.</i> 2013; <b>34</b>(14): 1041–9. <a target=xrefwindow id=d6966e1046 href="http://www.ncbi.nlm.nih.gov/pubmed/23257951">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1049 href="https://doi.org/10.1093/eurheartj/ehs435">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d6966e1058 class=n-a></a>Banerjee A, Fauchier L, Bernard-Brunet A, <i> et al.</i>: Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. <i>Thromb Haemost.</i> 2014; <b>111</b>(3): 549–56. <a target=xrefwindow id=d6966e1069 href="http://www.ncbi.nlm.nih.gov/pubmed/24452108">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1072 href="https://doi.org/10.1160/TH13-12-1033">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d6966e1081 class=n-a></a>Olesen JB, Torp-Pedersen C: Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher? <i>Thromb Haemost.</i> 2015; <b>113</b>(6): 1165–9. <a target=xrefwindow id=d6966e1089 href="http://www.ncbi.nlm.nih.gov/pubmed/25743201">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1092 href="https://doi.org/10.1160/TH15-02-0154">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d6966e1101 class=n-a></a>Nielsen PB, Chao TF: The risks of risk scores for stroke risk assessment in atrial fibrillation. <i>Thromb Haemost.</i> 2015; <b>113</b>(6): 1170–3. <a target=xrefwindow id=d6966e1109 href="http://www.ncbi.nlm.nih.gov/pubmed/25759209">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1112 href="https://doi.org/10.1160/TH15-03-0210">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d6966e1122 class=n-a></a>Dzeshka MS, Lip GY, Snezhitskiy V, <i> et al.</i>: Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. <i>J Am Coll Cardiol.</i> 2015; <b>66</b>(8): 943–59. <a target=xrefwindow id=d6966e1133 href="http://www.ncbi.nlm.nih.gov/pubmed/26293766">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1136 href="https://doi.org/10.1016/j.jacc.2015.06.1313">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d6966e1145 class=n-a></a>Allessie MA, de Groot NM, Houben RP, <i> et al.</i>: Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. <i>Circ Arrhythm Electrophysiol.</i> 2010; <b>3</b>(6): 606–15. <a target=xrefwindow id=d6966e1156 href="http://www.ncbi.nlm.nih.gov/pubmed/20719881">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1159 href="https://doi.org/10.1161/CIRCEP.109.910125">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d6966e1168 class=n-a></a>Shantsila E, Shantsila A, Blann AD, <i> et al.</i>: Left ventricular fibrosis in atrial fibrillation. <i>Am J Cardiol.</i> 2013; <b>111</b>(7): 996–1001. <a target=xrefwindow id=d6966e1179 href="http://www.ncbi.nlm.nih.gov/pubmed/23332595">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1182 href="https://doi.org/10.1016/j.amjcard.2012.12.005">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d6966e1191 class=n-a></a>Di Minno MN, Ambrosino P, Dello Russo A, <i> et al.</i>: Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature. <i>Thromb Haemost.</i> 2016; <b>115</b>(3): 663–77. <a target=xrefwindow id=d6966e1202 href="http://www.ncbi.nlm.nih.gov/pubmed/26607276">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1205 href="https://doi.org/10.1160/TH15-07-0532">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d6966e1214 class=n-a></a>Christensen LM, Krieger DW, Højberg S, <i> et al.</i>: Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. <i>Eur J Neurol.</i> 2014; <b>21</b>(6): 884–9. <a target=xrefwindow id=d6966e1225 href="http://www.ncbi.nlm.nih.gov/pubmed/24628954">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1228 href="https://doi.org/10.1111/ene.12400">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d6966e1237 class=n-a></a>Glotzer TV, Daoud EG, Wyse DG, <i> et al.</i>: The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. <i>Circ Arrhythm Electrophysiol.</i> 2009; <b>2</b>(5): 474–80. <a target=xrefwindow id=d6966e1248 href="http://www.ncbi.nlm.nih.gov/pubmed/19843914">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1251 href="https://doi.org/10.1161/CIRCEP.109.849638">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d6966e1261 class=n-a></a>Dobrev D, Friedrich A, Voigt N, <i> et al.</i>: The G protein-gated potassium current I<sub>K,ACh</sub> is constitutively active in patients with chronic atrial fibrillation. <i>Circulation.</i> 2005; <b>112</b>(24): 3697–706. <a target=xrefwindow id=d6966e1275 href="http://www.ncbi.nlm.nih.gov/pubmed/16330682">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1279 href="https://doi.org/10.1161/CIRCULATIONAHA.105.575332">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718526011"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1288 class=n-a></a>Barana A, Matamoros M, Dolz-Gaitón P, <i> et al.</i>: Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current. <i>Circ Arrhythm Electrophysiol.</i> 2014; <b>7</b>(5): 861–8. <a target=xrefwindow id=d6966e1299 href="http://www.ncbi.nlm.nih.gov/pubmed/25107449">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1302 href="https://doi.org/10.1161/CIRCEP.114.001709">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718526011">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d6966e1315 class=n-a></a>Llach A, Molina CE, Prat-Vidal C, <i> et al.</i>: Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A<sub>2A</sub> receptors. <i>Eur Heart J.</i> 2011; <b>32</b>(6): 721–9. <a target=xrefwindow id=d6966e1329 href="http://www.ncbi.nlm.nih.gov/pubmed/21177700">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1333 href="https://doi.org/10.1093/eurheartj/ehq464">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d6966e1342 class=n-a></a>Potpara TS, Polovina MM, Marinkovic JM, <i> et al.</i>: A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. <i>Int J Cardiol.</i> 2013; <b>168</b>(5): 4744–9. <a target=xrefwindow id=d6966e1353 href="http://www.ncbi.nlm.nih.gov/pubmed/23958417">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1356 href="https://doi.org/10.1016/j.ijcard.2013.07.234">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718334243"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1365 class=n-a></a>Lowres N, Neubeck L, Salkeld G, <i> et al.</i>: Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. <i>Thromb Haemost.</i> 2014; <b>111</b>(6): 1167–76. <a target=xrefwindow id=d6966e1376 href="http://www.ncbi.nlm.nih.gov/pubmed/24687081">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1379 href="https://doi.org/10.1160/TH14-03-0231">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718334243">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725382192"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1392 class=n-a></a>Sposato LA, Cipriano LE, Saposnik G, <i> et al.</i>: Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. <i>Lancet Neurol.</i> 2015; <b>14</b>(4): 377–87. <a target=xrefwindow id=d6966e1403 href="http://www.ncbi.nlm.nih.gov/pubmed/25748102">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1406 href="https://doi.org/10.1016/S1474-4422(15)70027-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725382192">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d6966e1420 class=n-a></a>Hobbs FD, Fitzmaurice DA, Mant J, <i> et al.</i>: A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. <i>Health Technol Assess.</i> 2005; <b>9</b>(40): iii–iv, ix–x, 1–74. <a target=xrefwindow id=d6966e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/16202350">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1434 href="https://doi.org/10.3310/hta9400">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718467600"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1443 class=n-a></a>Sanna T, Diener HC, Passman RS, <i> et al.</i>: Cryptogenic stroke and underlying atrial fibrillation. <i>N Engl J Med.</i> 2014; <b>370</b>(26): 2478–86. <a target=xrefwindow id=d6966e1454 href="http://www.ncbi.nlm.nih.gov/pubmed/24963567">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1457 href="https://doi.org/10.1056/NEJMoa1313600">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718467600">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718467601"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1470 class=n-a></a>Gladstone DJ, Spring M, Dorian P, <i> et al.</i>: Atrial fibrillation in patients with cryptogenic stroke. <i>N Engl J Med.</i> 2014; <b>370</b>(26): 2467–77. <a target=xrefwindow id=d6966e1481 href="http://www.ncbi.nlm.nih.gov/pubmed/24963566">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1484 href="https://doi.org/10.1056/NEJMoa1311376">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718467601">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d6966e1497 class=n-a></a>Stöllberger C, Chnupa P, Abzieher C, <i> et al.</i>: Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. <i>Clin Cardiol.</i> 2004; <b>27</b>(1): 40–6. <a target=xrefwindow id=d6966e1508 href="http://www.ncbi.nlm.nih.gov/pubmed/14743856">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1511 href="https://doi.org/10.1002/clc.4960270111">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d6966e1520 class=n-a></a>Cabin HS, Clubb KS, Hall C, <i> et al.</i>: Risk for systemic embolization of atrial fibrillation without mitral stenosis. <i>Am J Cardiol.</i> 1990; <b>65</b>(16): 1112–6. <a target=xrefwindow id=d6966e1531 href="http://www.ncbi.nlm.nih.gov/pubmed/2330896">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1534 href="https://doi.org/10.1016/0002-9149(90)90323-S">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d6966e1543 class=n-a></a>van Latum JC, Koudstaal PJ, Venables GS, <i> et al.</i>: Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. <i>Stroke.</i> 1995; <b>26</b>(5): 801–6. <a target=xrefwindow id=d6966e1554 href="http://www.ncbi.nlm.nih.gov/pubmed/7740570">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1557 href="https://doi.org/10.1161/01.STR.26.5.801">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d6966e1567 class=n-a></a>Lauw MN, Vanassche T, Masiero S, <i> et al.</i>: Abstract 20413: Pattern of Atrial Fibrillation and the Risk of Ischemic Stroke - A Systematic Review and Meta-Analysis. <i>Circulation.</i> 2014; <b>130</b>(Suppl 2): A20413. <a target=xrefwindow id=d6966e1578 href="http://circ.ahajournals.org/content/130/Suppl_2/A20413">Reference Source</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d6966e1587 class=n-a></a>Ganesan AN, Chew DP, Hartshorne T, <i> et al.</i>: The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. <i>Eur Heart J.</i> 2016; <b>37</b>(20): 1591–602. <a target=xrefwindow id=d6966e1598 href="http://www.ncbi.nlm.nih.gov/pubmed/26888184">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1601 href="https://doi.org/10.1093/eurheartj/ehw007">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718632713"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1610 class=n-a></a>Vanassche T, Lauw MN, Eikelboom JW, <i> et al.</i>: Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>Eur Heart J.</i> 2015; <b>36</b>(5): 281–7a. <a target=xrefwindow id=d6966e1621 href="http://www.ncbi.nlm.nih.gov/pubmed/25187524">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1624 href="https://doi.org/10.1093/eurheartj/ehu307">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718632713">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718871720"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1637 class=n-a></a>Steinberg BA, Hellkamp AS, Lokhnygina Y, <i> et al.</i>: Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>Eur Heart J.</i> 2015; <b>36</b>(5): 288–96. <a target=xrefwindow id=d6966e1648 href="http://www.ncbi.nlm.nih.gov/pubmed/25209598">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1651 href="https://doi.org/10.1093/eurheartj/ehu359">Publisher Full Text </a> | <a target=xrefwindow id=d6966e1655 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4313363">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718871720">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d6966e1668 class=n-a></a>January CT, Wann LS, Alpert JS, <i> et al.</i>: 2014 AHA/ACC/HRS Guideline for the&nbsp;Management of Patients With Atrial Fibrillation: Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol.</i> 2014; <b>64</b>(21): 2246–80. <a target=xrefwindow id=d6966e1679 href="https://doi.org/10.1016/j.jacc.2014.03.021">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d6966e1688 class=n-a></a>Blann AD, Lip GY: Renal, endothelial function, warfarin management, and the CHADS2, CHA2DS2VASc and HAS-BLED scores inpredicting MACE in AF. <i>Thromb Haemost.</i> 2015; <b>113</b>(5): 1155–7. <a target=xrefwindow id=d6966e1696 href="http://www.ncbi.nlm.nih.gov/pubmed/25716989">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1699 href="https://doi.org/10.1160/TH14-11-0932">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d6966e1709 class=n-a></a>Sjögren V, Grzymala-Lubanski B, Renlund H, <i> et al.</i>: Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. <i>Thromb Haemost.</i> 2015; <b>113</b>(6): 1370–7. <a target=xrefwindow id=d6966e1720 href="http://www.ncbi.nlm.nih.gov/pubmed/25716771">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1723 href="https://doi.org/10.1160/TH14-10-0859">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d6966e1732 class=n-a></a>Husted S, de Caterina R, Andreotti F, <i> et al.</i>: Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thromb Haemost.</i> 2014; <b>111</b>(5): 781–2. <a target=xrefwindow id=d6966e1743 href="http://www.ncbi.nlm.nih.gov/pubmed/24658395">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1746 href="https://doi.org/10.1160/TH14-03-0228">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d6966e1755 class=n-a></a>Ansell J, Crowther M, Burnett A, <i> et al.</i>: Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). <i>Thromb Haemost.</i> 2014; <b>112</b>(4): 841. <a target=xrefwindow id=d6966e1766 href="http://www.ncbi.nlm.nih.gov/pubmed/25119051">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1769 href="https://doi.org/10.1160/TH14-04-0325">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1474959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1778 class=n-a></a>Connolly SJ, Ezekowitz MD, Yusuf S, <i> et al.</i>: Dabigatran versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2009; <b>361</b>(10): 1139–51. <a target=xrefwindow id=d6966e1789 href="http://www.ncbi.nlm.nih.gov/pubmed/19717844">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1792 href="https://doi.org/10.1056/NEJMoa0905561">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1474959">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13262956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1805 class=n-a></a>Patel MR, Mahaffey KW, Garg J, <i> et al.</i>: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <i>N Engl J Med.</i> 2011; <b>365</b>(10): 883–91. <a target=xrefwindow id=d6966e1816 href="http://www.ncbi.nlm.nih.gov/pubmed/21830957">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1819 href="https://doi.org/10.1056/NEJMoa1009638">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13262956">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13199976"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1832 class=n-a></a>Granger CB, Alexander JH, McMurray JJ, <i> et al.</i>: Apixaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2011; <b>365</b>(11): 981–92. <a target=xrefwindow id=d6966e1843 href="http://www.ncbi.nlm.nih.gov/pubmed/21870978">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1846 href="https://doi.org/10.1056/NEJMoa1107039">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13199976">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718181700"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1860 class=n-a></a>Giugliano RP, Ruff CT, Braunwald E, <i> et al.</i>: Edoxaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2013; <b>369</b>(22): 2093–104. <a target=xrefwindow id=d6966e1871 href="http://www.ncbi.nlm.nih.gov/pubmed/24251359">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1874 href="https://doi.org/10.1056/NEJMoa1310907">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718181700">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718128600"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1887 class=n-a></a>Majeed A, Hwang HG, Connolly SJ, <i> et al.</i>: Management and outcomes of major bleeding during treatment with dabigatran or warfarin. <i>Circulation.</i> 2013; <b>128</b>(21): 2325–32. <a target=xrefwindow id=d6966e1898 href="http://www.ncbi.nlm.nih.gov/pubmed/24081972">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1901 href="https://doi.org/10.1161/CIRCULATIONAHA.113.002332">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718128600">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718321437"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1914 class=n-a></a>Hylek EM, Held C, Alexander JH, <i> et al.</i>: Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. <i>J Am Coll Cardiol.</i> 2014; <b>63</b>(20): 2141–7. <a target=xrefwindow id=d6966e1925 href="http://www.ncbi.nlm.nih.gov/pubmed/24657685">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1928 href="https://doi.org/10.1016/j.jacc.2014.02.549">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718321437">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718321588"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e1941 class=n-a></a>Piccini JP, Garg J, Patel MR, <i> et al.</i>: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>Eur Heart J.</i> 2014; <b>35</b>(28): 1873–80. <a target=xrefwindow id=d6966e1952 href="http://www.ncbi.nlm.nih.gov/pubmed/24658769">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1955 href="https://doi.org/10.1093/eurheartj/ehu083">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718321588">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d6966e1968 class=n-a></a>Connolly SJ, Ezekowitz MD, Yusuf S, <i> et al.</i>: Newly identified events in the RE-LY trial. <i>N Engl J Med.</i> 2010; <b>363</b>(19): 1875–6. <a target=xrefwindow id=d6966e1979 href="http://www.ncbi.nlm.nih.gov/pubmed/21047252">PubMed Abstract </a> | <a target=xrefwindow id=d6966e1982 href="https://doi.org/10.1056/NEJMc1007378">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d6966e1991 class=n-a></a>Oldgren J, Alings M, Darius H, <i> et al.</i>: Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS<sub>2</sub> score: a subgroup analysis of the RE-LY trial. <i>Ann Intern Med.</i> 2011; <b>155</b>(10): 660–7, W204. <a target=xrefwindow id=d6966e2005 href="http://www.ncbi.nlm.nih.gov/pubmed/22084332">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2009 href="https://doi.org/10.7326/0003-4819-155-10-201111150-00004">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d6966e2019 class=n-a></a>Darwiche W, Bejan-Angoulvant T, Angoulvant D, <i> et al.</i>: Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. <i>Thromb Haemost.</i> 2016; <b>116</b>(6): 1150–8. <a target=xrefwindow id=d6966e2030 href="http://www.ncbi.nlm.nih.gov/pubmed/27580712">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2033 href="https://doi.org/10.1160/TH16-06-0483">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d6966e2042 class=n-a></a>Seeger JD, Bykov K, Bartels DB, <i> et al.</i>: Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. <i>Thromb Haemost.</i> 2015; <b>114</b>(6): 1277–89. <a target=xrefwindow id=d6966e2053 href="http://www.ncbi.nlm.nih.gov/pubmed/26446507">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2056 href="https://doi.org/10.1160/TH15-06-0497">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d6966e2065 class=n-a></a>Lip GY, Keshishian A, Kamble S, <i> et al.</i>: Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. <i>Thromb Haemost.</i> 2016; <b>116</b>(5): 975–86. <a target=xrefwindow id=d6966e2076 href="http://www.ncbi.nlm.nih.gov/pubmed/27538358">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2079 href="https://doi.org/10.1160/TH16-05-0403">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726584229"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2088 class=n-a></a>Carmo J, Moscoso Costa F, Ferreira J, <i> et al.</i>: Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. <i>Thromb Haemost.</i> 2016; <b>116</b>(4): 754–63. <a target=xrefwindow id=d6966e2099 href="http://www.ncbi.nlm.nih.gov/pubmed/27465747">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2102 href="https://doi.org/10.1160/TH16-03-0203">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726584229">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d6966e2115 class=n-a></a>Eikelboom JW, Connolly SJ, Gao P, <i> et al.</i>: Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. <i>J Stroke Cerebrovasc Dis.</i> 2012; <b>21</b>(6): 429–35. <a target=xrefwindow id=d6966e2126 href="http://www.ncbi.nlm.nih.gov/pubmed/22818021">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2129 href="https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.05.007">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717961928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2138 class=n-a></a>Lopes RD, Al-Khatib SM, Wallentin L, <i> et al.</i>: Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet.</i> 2012; <b>380</b>(9855): 1749–58. <a target=xrefwindow id=d6966e2149 href="http://www.ncbi.nlm.nih.gov/pubmed/23036896">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2152 href="https://doi.org/10.1016/S0140-6736(12)60986-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717961928">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d6966e2166 class=n-a></a>Eikelboom JW, O'Donnell M, Yusuf S, <i> et al.</i>: Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <i>Am Heart J.</i> 2010; <b>159</b>(3): 348–353.e1. <a target=xrefwindow id=d6966e2177 href="http://www.ncbi.nlm.nih.gov/pubmed/20211294">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2180 href="https://doi.org/10.1016/j.ahj.2009.08.026">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/9310957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2189 class=n-a></a>Connolly SJ, Eikelboom J, Joyner C, <i> et al.</i>: Apixaban in patients with atrial fibrillation. <i>N Engl J Med.</i> 2011; <b>364</b>(9): 806–17. <a target=xrefwindow id=d6966e2200 href="http://www.ncbi.nlm.nih.gov/pubmed/21309657">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2203 href="https://doi.org/10.1056/NEJMoa1007432">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/9310957">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725291301"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2216 class=n-a></a>Granger CB, Lopes RD, Hanna M, <i> et al.</i>: Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Am Heart J.</i> 2015; <b>169</b>(1): 25–30. <a target=xrefwindow id=d6966e2227 href="http://www.ncbi.nlm.nih.gov/pubmed/25497244">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2230 href="https://doi.org/10.1016/j.ahj.2014.09.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725291301">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725704045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2243 class=n-a></a>Martinez C, Katholing A, Wallenhorst C, <i> et al.</i>: Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. <i>Thromb Haemost.</i> 2016; <b>115</b>(1): 31–9. <a target=xrefwindow id=d6966e2254 href="http://www.ncbi.nlm.nih.gov/pubmed/26246112">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2257 href="https://doi.org/10.1160/TH15-04-0350">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725704045">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726738759"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2270 class=n-a></a>Beyer-Westendorf J, Camm AJ, Coleman CI, <i> et al.</i>: Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thromb Haemost.</i> 2016; <b>116</b>(Suppl. 2): S13–S23. <a target=xrefwindow id=d6966e2281 href="http://www.ncbi.nlm.nih.gov/pubmed/27623681">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2284 href="https://doi.org/10.1160/TH16-06-0485">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726738759">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726092468"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2297 class=n-a></a>Hecker J, Marten S, Keller L, <i> et al.</i>: Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. <i>Thromb Haemost.</i> 2016; <b>115</b>(5): 939–49. <a target=xrefwindow id=d6966e2308 href="http://www.ncbi.nlm.nih.gov/pubmed/26791999">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2311 href="https://doi.org/10.1160/TH15-10-0840">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726092468">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d6966e2325 class=n-a></a>Blann AD, Skjoth F, Rasmussen LH, <i> et al.</i>: Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. <i>Thromb Haemost.</i> 2015; <b>114</b>(2): 403–9. <a target=xrefwindow id=d6966e2336 href="http://www.ncbi.nlm.nih.gov/pubmed/26062437">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2339 href="https://doi.org/10.1160/TH15-05-0383">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d6966e2348 class=n-a></a>Hobl E, Jilma B: Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects. <i>Thromb Haemost.</i> 2015; <b>113</b>(6): 1162–3. <a target=xrefwindow id=d6966e2356 href="http://www.ncbi.nlm.nih.gov/pubmed/25926042">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2359 href="https://doi.org/10.1160/TH15-04-0324">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725579799"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2368 class=n-a></a>Pollack CV Jr, Reilly PA, Eikelboom J, <i> et al.</i>: Idarucizumab for Dabigatran Reversal. <i>N Engl J Med.</i> 2015; <b>373</b>(6): 511–20. <a target=xrefwindow id=d6966e2379 href="http://www.ncbi.nlm.nih.gov/pubmed/26095746">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2382 href="https://doi.org/10.1056/NEJMoa1502000">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725579799">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725396656"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2395 class=n-a></a>Glund S, Moschetti V, Norris S, <i> et al.</i>: A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. <i>Thromb Haemost.</i> 2015; <b>113</b>(5): 943–51. <a target=xrefwindow id=d6966e2406 href="http://www.ncbi.nlm.nih.gov/pubmed/25789661">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2409 href="https://doi.org/10.1160/TH14-12-1080">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725396656">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d6966e2422 class=n-a></a>Pollack CV Jr, Reilly PA, Bernstein R, <i> et al.</i>: Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thromb Haemost.</i> 2015; <b>114</b>(1): 198–205. <a target=xrefwindow id=d6966e2433 href="http://www.ncbi.nlm.nih.gov/pubmed/26020620">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2436 href="https://doi.org/10.1160/TH15-03-0192">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725418418"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2445 class=n-a></a>Greinacher A, Thiele T, Selleng K: Reversal of anticoagulants: an overview of current developments. <i>Thromb Haemost.</i> 2015; <b>113</b>(5): 931–42. <a target=xrefwindow id=d6966e2453 href="http://www.ncbi.nlm.nih.gov/pubmed/25832311">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2456 href="https://doi.org/10.1160/TH14-11-0982">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725418418">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727006374"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2470 class=n-a></a>Ansell JE, Bakhru SH, Laulicht BE, <i> et al.</i>: Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. <i>Thromb Haemost.</i> 2016. <a target=xrefwindow id=d6966e2478 href="http://www.ncbi.nlm.nih.gov/pubmed/27853809">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2481 href="https://doi.org/10.1160/TH16-03-0224">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727006374">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d6966e2494 class=n-a></a>Lane DA, Lip GY: Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. <i>Thromb Haemost.</i> 2014; <b>111</b>(3): 381–3. <a target=xrefwindow id=d6966e2502 href="http://www.ncbi.nlm.nih.gov/pubmed/24477628">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2505 href="https://doi.org/10.1160/TH14-01-0063">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d6966e2514 class=n-a></a>Lane DA, Aguinaga L, Blomström-Lundqvist C, <i> et al.</i>: Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). <i>Europace.</i> 2015; <b>17</b>(12): 1747–69. <a target=xrefwindow id=d6966e2525 href="http://www.ncbi.nlm.nih.gov/pubmed/26108807">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2528 href="https://doi.org/10.1093/europace/euv233">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718201417"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2537 class=n-a></a>Ruff CT, Giugliano RP, Braunwald E, <i> et al.</i>: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet.</i> 2014; <b>383</b>(9921): 955–62. <a target=xrefwindow id=d6966e2548 href="http://www.ncbi.nlm.nih.gov/pubmed/24315724">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2551 href="https://doi.org/10.1016/S0140-6736(13)62343-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718201417">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d6966e2564 class=n-a></a>NICE: Atrial Fibrillation: management. Clinical Guideline. 2014. <a target=xrefwindow id=d6966e2566 href="https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-35109805981381">Reference Source</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d6966e2575 class=n-a></a>Freedman B, Lip GY: "Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation. <i>Thromb Haemost.</i> 2016; <b>116</b>(4): 587–9. <a target=xrefwindow id=d6966e2583 href="http://www.ncbi.nlm.nih.gov/pubmed/27580884">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2586 href="https://doi.org/10.1160/TH16-08-0658">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d6966e2596 class=n-a></a>Potpara TS: Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation. <i>Thromb Haemost.</i> 2015; <b>114</b>(6): 1093–8. <a target=xrefwindow id=d6966e2604 href="http://www.ncbi.nlm.nih.gov/pubmed/26559559">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2607 href="https://doi.org/10.1160/TH15-10-0825">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725840371"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2616 class=n-a></a>Villines TC, Schnee J, Fraeman K, <i> et al.</i>: A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. <i>Thromb Haemost.</i> 2015; <b>114</b>(6): 1290–8. <a target=xrefwindow id=d6966e2627 href="http://www.ncbi.nlm.nih.gov/pubmed/26446456">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2630 href="https://doi.org/10.1160/TH15-06-0453">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725840371">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d6966e2643 class=n-a></a>Avgil-Tsadok M, Jackevicius CA, Essebag V, <i> et al.</i>: Dabigatran use in elderly patients with atrial fibrillation. <i>Thromb Haemost.</i> 2016; <b>115</b>(1): 152–60. <a target=xrefwindow id=d6966e2654 href="http://www.ncbi.nlm.nih.gov/pubmed/26354766">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2657 href="https://doi.org/10.1160/TH15-03-0247">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725765390"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2666 class=n-a></a>Camm AJ, Amarenco P, Haas S, <i> et al.</i>: XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>Eur Heart J.</i> 2016; <b>37</b>(14): 1145–53. <a target=xrefwindow id=d6966e2677 href="http://www.ncbi.nlm.nih.gov/pubmed/26330425">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2680 href="https://doi.org/10.1093/eurheartj/ehv466">Publisher Full Text </a> | <a target=xrefwindow id=d6966e2684 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4823634">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725765390">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726745263"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2697 class=n-a></a>Coleman CI, Antz M, Bowrin K, <i> et al.</i>: Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. <i>Curr Med Res Opin.</i> 2016; <b>32</b>(12): 2047–53. <a target=xrefwindow id=d6966e2708 href="http://www.ncbi.nlm.nih.gov/pubmed/27633045">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2711 href="https://doi.org/10.1080/03007995.2016.1237937">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726745263">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726472493"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2724 class=n-a></a>Bassand JP, Accetta G, Camm AJ, <i> et al.</i>: Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>Eur Heart J.</i> 2016; <b>37</b>(38): 2882–2889. <a target=xrefwindow id=d6966e2735 href="http://www.ncbi.nlm.nih.gov/pubmed/27357359">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2738 href="https://doi.org/10.1093/eurheartj/ehw233">Publisher Full Text </a> | <a target=xrefwindow id=d6966e2742 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5070447">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726472493">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726757943"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2756 class=n-a></a>Hernandez I, Zhang Y: Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. <i>Am J Cardiovasc Drugs.</i> 2016. <a target=xrefwindow id=d6966e2761 href="http://www.ncbi.nlm.nih.gov/pubmed/27637493">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2764 href="https://doi.org/10.1007/s40256-016-0189-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726757943">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726667162"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2777 class=n-a></a>Lip GY, Pan X, Kamble S, <i> et al.</i>: Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. <i>Int J Clin Pract.</i> 2016; <b>70</b>(9): 752–63. <a target=xrefwindow id=d6966e2788 href="http://www.ncbi.nlm.nih.gov/pubmed/27550177">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2791 href="https://doi.org/10.1111/ijcp.12863">Publisher Full Text </a> | <a target=xrefwindow id=d6966e2795 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5129572">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726667162">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1164334"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2808 class=n-a></a>Holmes DR, Reddy VY, Turi ZG, <i> et al.</i>: Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. <i>Lancet.</i> 2009; <b>374</b>(9689): 534–42. <a target=xrefwindow id=d6966e2819 href="http://www.ncbi.nlm.nih.gov/pubmed/19683639">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2822 href="https://doi.org/10.1016/S0140-6736(09)61343-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1164334">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718482831"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2835 class=n-a></a>Holmes DR Jr, Kar S, Price MJ, <i> et al.</i>: Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. <i>J Am Coll Cardiol.</i> 2014; <b>64</b>(1): 1–12. <a target=xrefwindow id=d6966e2846 href="http://www.ncbi.nlm.nih.gov/pubmed/24998121">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2849 href="https://doi.org/10.1016/j.jacc.2014.04.029">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718482831">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725579872"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2862 class=n-a></a>Holmes DR Jr, Doshi SK, Kar S, <i> et al.</i>: Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. <i>J Am Coll Cardiol.</i> 2015; <b>65</b>(24): 2614–23. <a target=xrefwindow id=d6966e2873 href="http://www.ncbi.nlm.nih.gov/pubmed/26088300">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2876 href="https://doi.org/10.1016/j.jacc.2015.04.025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725579872">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717995512"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2889 class=n-a></a>Alli O, Doshi S, Kar S, <i> et al.</i>: Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. <i>J Am Coll Cardiol.</i> 2013; <b>61</b>(17): 1790–8. <a target=xrefwindow id=d6966e2900 href="http://www.ncbi.nlm.nih.gov/pubmed/23500276">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2903 href="https://doi.org/10.1016/j.jacc.2013.01.061">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717995512">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725980400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2917 class=n-a></a>Price MJ, Reddy VY, Valderrabano M, <i> et al.</i>: Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. <i>JACC Cardiovasc Interv.</i> 2015; <b>8</b>(15): 1925–32. <a target=xrefwindow id=d6966e2928 href="http://www.ncbi.nlm.nih.gov/pubmed/26627989">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2931 href="https://doi.org/10.1016/j.jcin.2015.08.035">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725980400">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726190752"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2944 class=n-a></a>Panikker S, Lord J, Jarman JW, <i> et al.</i>: Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation. <i>Eur Heart J.</i> 2016; pii: ehw048.<a target=xrefwindow id=d6966e2952 href="http://www.ncbi.nlm.nih.gov/pubmed/26935273">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2955 href="https://doi.org/10.1093/eurheartj/ehw048">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726190752">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725323928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2968 class=n-a></a>Tzikas A, Shakir S, Gafoor S, <i> et al.</i>: Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. <i>EuroIntervention.</i> 2016; <b>11</b>(10): 1170–9. <a target=xrefwindow id=d6966e2979 href="http://www.ncbi.nlm.nih.gov/pubmed/25604089">PubMed Abstract </a> | <a target=xrefwindow id=d6966e2982 href="https://doi.org/10.4244/EIJY15M01_06">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725323928">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726144883"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6966e2995 class=n-a></a>Lakkireddy D, Afzal MR, Lee RJ, <i> et al.</i>: Short and long-term outcomes of percutaneous left atrial appendage suture ligation: Results from a US multicenter evaluation. <i>Heart Rhythm.</i> 2016; <b>13</b>(5): 1030–6. <a target=xrefwindow id=d6966e3006 href="http://www.ncbi.nlm.nih.gov/pubmed/26872554">PubMed Abstract </a> | <a target=xrefwindow id=d6966e3009 href="https://doi.org/10.1016/j.hrthm.2016.01.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726144883">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Dec 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2887.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2887.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> University of Birmingham Institute of Cardiovascular Sciences, Birmingham, UK<br/> <sup>2</sup> Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2887/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 20 Dec 2016, 5:2887 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.10176.1">https://doi.org/10.12688/f1000research.10176.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Shahid F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10962 data-id=10176 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10176.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2887/v1/pdf?article_uuid=cc03691d-d215-4bfa-9ca3-ed03eb5c7920" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.10176.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Shahid F, Shantsila E and Lip GYH. Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention [version 1; peer review: 3 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2887 (<a href="https://doi.org/10.12688/f1000research.10176.1" target=_blank>https://doi.org/10.12688/f1000research.10176.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=10176 id=mobile-track-article-signin-10176 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10176?target=/articles/5-2887.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10962 /> <input name=articleId type=hidden value=10176 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>David R. Holmes</strong>, Mayo Clinic, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>John Zafiris</strong>, George Papanikolaou General Hospital, Greece </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Victor Serebrauny</strong>, Johns Hopkins University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Dec 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2887.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2887.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19064-18640></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19065-18632></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19063-18637></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2887/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>20 Dec 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>David R. Holmes</strong>, Mayo Clinic, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>John Zafiris</strong>, George Papanikolaou General Hospital, Greece </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Victor Serebrauny</strong>, Johns Hopkins University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2887.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2887/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the understanding and...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2887/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2887/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2887/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Shahid F et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2887/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2887",
            templates : {
                twitter : "Recent advances in the understanding and management of atrial.... Shahid F et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2887/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/10176/10962")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10962");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "18640": 0,
                           "18632": 0,
                           "18637": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "c4e64aba-cb12-4959-832e-eb10a79f39a4";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2887.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2887.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2887.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2887.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2887.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>